Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold ...

Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

Aktis Oncology (AKTS), a radio pharma startup backed by pharma giants such as Eli Lilly (LLY) has submitted initial filings ...

Indiana University’s Lilly Library is set to receive a large grant to enhance public understanding of the role religion plays in public life.